Jazz Pharmaceuticals to Showcase Innovations in Neurology at AAN Annual Meeting At the upcoming 2026 AAN Annual Meeting, Jazz Pharmaceuticals will present significant research on Epidiolex and Xywav, targeting rare neurological disorders.

Jazz Pharmaceuticals to Showcase Innovations in Neurology at AAN Annual Meeting #United_States #Chicago #Jazz_Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Reports Strong Financial Performance for 2025 and Projects Growth for 2026 Jazz Pharmaceuticals has announced a remarkable financial performance in 2025, with $4.3 billion in total revenue. The company anticipates continued growth in 2026 supported by robust new product launches.

Jazz Pharmaceuticals Reports Strong Financial Performance for 2025 and Projects Growth for 2026 #USA #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

Xywav Patient Tips: 7 things you should know Easy-to-read patient tips for Xywav covering how it works, benefits, risks, and best practices.

#Xywav treats narcolepsy and idiopathic hypersomnia with 92% less sodium than Xyrem, using mixed mineral salts. Fewer side effects but still high abuse potential. Requires REMS-enrolled prescriber and certified pharmacy dispensing only. www.drugs.com/tips/xywav-p...

Transformative Findings on Xywav® Treatment Presented at Global Sleep and Psychiatry Events Jazz Pharmaceuticals recently unveiled pivotal Phase 4 data and real-world evidence for Xywav® treatment in narcolepsy during major international conferences.

Transformative Findings on Xywav® Treatment Presented at Global Sleep and Psychiatry Events #None #Jazz_Pharmaceuticals #Narcolepsy #Xywav

Jazz Pharmaceuticals Reports Strong Q2 2025 Results and Leadership Change Jazz Pharmaceuticals announced its Q2 2025 financial results, showcasing significant revenue growth and updating its financial guidance. A new CEO will take the helm, driving future growth.

Jazz Pharmaceuticals Reports Strong Q2 2025 Results and Leadership Change #USA #Dublin #Jazz_Pharmaceuticals #Xywav #Zepzelca

Jazz Pharmaceuticals Reports Second Quarter 2025 Performance and CEO Transition Jazz Pharmaceuticals announces its financial results for Q2 2025, showcasing revenue growth and key updates on its pipeline and leadership transition.

Jazz Pharmaceuticals Reports Second Quarter 2025 Performance and CEO Transition #USA #Dublin #Jazz_Pharmaceuticals #Xywav #Zepzelca

Jazz Pharmaceuticals Unveils New Data on Xywav Treatment for Narcolepsy at SLEEP 2025 Conference At SLEEP 2025, Jazz Pharmaceuticals presented significant Phase 4 findings on their low-sodium oxybate Xywav for narcolepsy treatment, showcasing promising outcomes.

Jazz Pharmaceuticals Unveils New Data on Xywav Treatment for Narcolepsy at SLEEP 2025 Conference #Ireland #Dublin #Jazz_Pharmaceuticals #Narcolepsy #Xywav

Jazz Pharmaceuticals To Showcase Groundbreaking Research on Xywav® for Sleep Disorders at SLEEP 2025 Jazz Pharmaceuticals will present 19 abstracts, including 11 late-breaking studies on Xywav® for sleep disorders at SLEEP 2025, highlighting its treatment benefits.

Jazz Pharmaceuticals To Showcase Groundbreaking Research on Xywav® for Sleep Disorders at SLEEP 2025 #USA #Seattle #Jazz_Pharmaceuticals #Xywav #SLEEP_2025

Jazz Pharmaceuticals Reports First Quarter 2025 Financial Results and Adjustments to Future Guidance Discover the latest financial performance and updates from Jazz Pharmaceuticals for the first quarter of 2025, revealing trends and future plans.

Jazz Pharmaceuticals Reports First Quarter 2025 Financial Results and Adjustments to Future Guidance #United_States #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Reports Strong Q1 2025 Financial Results and Updates Guidance for the Year Ahead Jazz Pharmaceuticals PLC demonstrates resilience with $898M in revenues for Q1 2025, driven by growth in key products. The company updates its financial outlook reflecting positive business trends.

Jazz Pharmaceuticals Reports Strong Q1 2025 Financial Results and Updates Guidance for the Year Ahead #USA #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

After experiencing severe tremors and anxiety/depression at 6g dose, my pulmanologist reduced dosage to 3g. Aforementioned negative effects reduced some but remain present and intrusive. I'm done with Xywav. Not for me. #xywav #sleepdisorder #excessivedaytimesleepiness

Cognitive shuffling: A mental trick to help you quiet racing thoughts and fall asleep | CNN Cognitive shuffling is a word-based mental technique designed to help quiet racing thoughts and ease your brain into sleep.

When #xywav leaves you wide awake short of your sleep goal, try the following. It kinda works for me. #xywav www.cnn.com/2025/04/08/h...

Diagnosed with Excessive Daytime Sleepiness and prescribed #xywav. The 6g dosage caused severe tremors, could not keep food on my fork, and anxiety. I’ve backed down to 4.5g tremors and anxiety have moderated but now I’m only getting 5 hrs sleep. #sleepdisorder #xywav

Jazz Pharmaceuticals Presents Innovative Research on Xywav® and Epidiolex® at AAN Annual Meeting Jazz Pharmaceuticals reveals significant findings on Xywav® and Epidiolex®, showcasing their commitment to addressing neurological disorders at the 2025 AAN Annual Meeting.

Jazz Pharmaceuticals Presents Innovative Research on Xywav® and Epidiolex® at AAN Annual Meeting #Ireland #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Unveils Strong Financial Performance for 2024 and 2025 Outlook Jazz Pharmaceuticals has announced impressive fourth-quarter and full-year financial results for 2024, highlighting significant revenue growth and promising projections for 2025.

Jazz Pharmaceuticals Unveils Strong Financial Performance for 2024 and 2025 Outlook #Ireland #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

I know i should be happy this new medicine ( #xywav) is waking me up early but i hate it.... I like sleeping, i just wanted to feel more awake when i want to be awake. 😒

But forced myself to do a little work out since i don't have a legitimate excuse 😑